Cargando…
Systemic Inhibition of NF-κB Activation Protects from Silicosis
BACKGROUND: Silicosis is a complex lung disease for which no successful treatment is available and therefore lung transplantation is a potential alternative. Tumor necrosis factor alpha (TNFα) plays a central role in the pathogenesis of silicosis. TNFα signaling is mediated by the transcription fact...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2682759/ https://www.ncbi.nlm.nih.gov/pubmed/19479048 http://dx.doi.org/10.1371/journal.pone.0005689 |
_version_ | 1782167089481515008 |
---|---|
author | Di Giuseppe, Michelangelo Gambelli, Federica Hoyle, Gary W. Lungarella, Giuseppe Studer, Sean M. Richards, Thomas Yousem, Sam McCurry, Ken Dauber, James Kaminski, Naftali Leikauf, George Ortiz, Luis A. |
author_facet | Di Giuseppe, Michelangelo Gambelli, Federica Hoyle, Gary W. Lungarella, Giuseppe Studer, Sean M. Richards, Thomas Yousem, Sam McCurry, Ken Dauber, James Kaminski, Naftali Leikauf, George Ortiz, Luis A. |
author_sort | Di Giuseppe, Michelangelo |
collection | PubMed |
description | BACKGROUND: Silicosis is a complex lung disease for which no successful treatment is available and therefore lung transplantation is a potential alternative. Tumor necrosis factor alpha (TNFα) plays a central role in the pathogenesis of silicosis. TNFα signaling is mediated by the transcription factor, Nuclear Factor (NF)-κB, which regulates genes controlling several physiological processes including the innate immune responses, cell death, and inflammation. Therefore, inhibition of NF-κB activation represents a potential therapeutic strategy for silicosis. METHODS/FINDINGS: In the present work we evaluated the lung transplant database (May 1986–July 2007) at the University of Pittsburgh to study the efficacy of lung transplantation in patients with silicosis (n = 11). We contrasted the overall survival and rate of graft rejection in these patients to that of patients with idiopathic pulmonary fibrosis (IPF, n = 79) that was selected as a control group because survival benefit of lung transplantation has been identified for these patients. At the time of lung transplantation, we found the lungs of silica-exposed subjects to contain multiple foci of inflammatory cells and silicotic nodules with proximal TNFα expressing macrophage and NF-κB activation in epithelial cells. Patients with silicosis had poor survival (median survival 2.4 yr; confidence interval (CI): 0.16–7.88 yr) compared to IPF patients (5.3 yr; CI: 2.8–15 yr; p = 0.07), and experienced early rejection of their lung grafts (0.9 yr; CI: 0.22–0.9 yr) following lung transplantation (2.4 yr; CI:1.5–3.6 yr; p<0.05). Using a mouse experimental model in which the endotracheal instillation of silica reproduces the silica-induced lung injury observed in humans we found that systemic inhibition of NF-κB activation with a pharmacologic inhibitor (BAY 11-7085) of IκBα phosphorylation decreased silica-induced inflammation and collagen deposition. In contrast, transgenic mice expressing a dominant negative IκBα mutant protein under the control of epithelial cell specific promoters demonstrate enhanced apoptosis and collagen deposition in their lungs in response to silica. CONCLUSIONS: Although limited by its size, our data support that patients with silicosis appear to have poor outcome following lung transplantation. Experimental data indicate that while the systemic inhibition of NF-κB protects from silica-induced lung injury, epithelial cell specific NF-κB inhibition appears to aggravate the outcome of experimental silicosis. |
format | Text |
id | pubmed-2682759 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2009 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-26827592009-05-27 Systemic Inhibition of NF-κB Activation Protects from Silicosis Di Giuseppe, Michelangelo Gambelli, Federica Hoyle, Gary W. Lungarella, Giuseppe Studer, Sean M. Richards, Thomas Yousem, Sam McCurry, Ken Dauber, James Kaminski, Naftali Leikauf, George Ortiz, Luis A. PLoS One Research Article BACKGROUND: Silicosis is a complex lung disease for which no successful treatment is available and therefore lung transplantation is a potential alternative. Tumor necrosis factor alpha (TNFα) plays a central role in the pathogenesis of silicosis. TNFα signaling is mediated by the transcription factor, Nuclear Factor (NF)-κB, which regulates genes controlling several physiological processes including the innate immune responses, cell death, and inflammation. Therefore, inhibition of NF-κB activation represents a potential therapeutic strategy for silicosis. METHODS/FINDINGS: In the present work we evaluated the lung transplant database (May 1986–July 2007) at the University of Pittsburgh to study the efficacy of lung transplantation in patients with silicosis (n = 11). We contrasted the overall survival and rate of graft rejection in these patients to that of patients with idiopathic pulmonary fibrosis (IPF, n = 79) that was selected as a control group because survival benefit of lung transplantation has been identified for these patients. At the time of lung transplantation, we found the lungs of silica-exposed subjects to contain multiple foci of inflammatory cells and silicotic nodules with proximal TNFα expressing macrophage and NF-κB activation in epithelial cells. Patients with silicosis had poor survival (median survival 2.4 yr; confidence interval (CI): 0.16–7.88 yr) compared to IPF patients (5.3 yr; CI: 2.8–15 yr; p = 0.07), and experienced early rejection of their lung grafts (0.9 yr; CI: 0.22–0.9 yr) following lung transplantation (2.4 yr; CI:1.5–3.6 yr; p<0.05). Using a mouse experimental model in which the endotracheal instillation of silica reproduces the silica-induced lung injury observed in humans we found that systemic inhibition of NF-κB activation with a pharmacologic inhibitor (BAY 11-7085) of IκBα phosphorylation decreased silica-induced inflammation and collagen deposition. In contrast, transgenic mice expressing a dominant negative IκBα mutant protein under the control of epithelial cell specific promoters demonstrate enhanced apoptosis and collagen deposition in their lungs in response to silica. CONCLUSIONS: Although limited by its size, our data support that patients with silicosis appear to have poor outcome following lung transplantation. Experimental data indicate that while the systemic inhibition of NF-κB protects from silica-induced lung injury, epithelial cell specific NF-κB inhibition appears to aggravate the outcome of experimental silicosis. Public Library of Science 2009-05-25 /pmc/articles/PMC2682759/ /pubmed/19479048 http://dx.doi.org/10.1371/journal.pone.0005689 Text en Di Giuseppe et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Di Giuseppe, Michelangelo Gambelli, Federica Hoyle, Gary W. Lungarella, Giuseppe Studer, Sean M. Richards, Thomas Yousem, Sam McCurry, Ken Dauber, James Kaminski, Naftali Leikauf, George Ortiz, Luis A. Systemic Inhibition of NF-κB Activation Protects from Silicosis |
title | Systemic Inhibition of NF-κB Activation Protects from Silicosis |
title_full | Systemic Inhibition of NF-κB Activation Protects from Silicosis |
title_fullStr | Systemic Inhibition of NF-κB Activation Protects from Silicosis |
title_full_unstemmed | Systemic Inhibition of NF-κB Activation Protects from Silicosis |
title_short | Systemic Inhibition of NF-κB Activation Protects from Silicosis |
title_sort | systemic inhibition of nf-κb activation protects from silicosis |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2682759/ https://www.ncbi.nlm.nih.gov/pubmed/19479048 http://dx.doi.org/10.1371/journal.pone.0005689 |
work_keys_str_mv | AT digiuseppemichelangelo systemicinhibitionofnfkbactivationprotectsfromsilicosis AT gambellifederica systemicinhibitionofnfkbactivationprotectsfromsilicosis AT hoylegaryw systemicinhibitionofnfkbactivationprotectsfromsilicosis AT lungarellagiuseppe systemicinhibitionofnfkbactivationprotectsfromsilicosis AT studerseanm systemicinhibitionofnfkbactivationprotectsfromsilicosis AT richardsthomas systemicinhibitionofnfkbactivationprotectsfromsilicosis AT yousemsam systemicinhibitionofnfkbactivationprotectsfromsilicosis AT mccurryken systemicinhibitionofnfkbactivationprotectsfromsilicosis AT dauberjames systemicinhibitionofnfkbactivationprotectsfromsilicosis AT kaminskinaftali systemicinhibitionofnfkbactivationprotectsfromsilicosis AT leikaufgeorge systemicinhibitionofnfkbactivationprotectsfromsilicosis AT ortizluisa systemicinhibitionofnfkbactivationprotectsfromsilicosis |